摘要
目的:研究帕利哌酮缓释片治疗首发精神分裂症的临床疗效。方法:2018年5月-2019年5月收治首发精神分裂症患者90例,随机分为两组,各45例。对照组使用利培酮治疗;观察组使用帕利哌酮缓释片治疗。分析两组治疗效果。结果:观察组治疗2周末阳性与阴性症状量表(PANSS)评分总分及治疗2、4、8周PANSS阴性评分均明显低于对照组,差异有统计学意义(P<0.05)。两组患者治疗总有效率比较,差异无统计学意义(P>0.05)。观察组不良反应发生率明显低于对照组,差异有统计学意义(P<0.05)。结论:利用帕利哌酮缓释片治疗首发精神分裂症效果较好,整个治疗过程中不良反应发生率非常低,具有较高临床应用价值。
Objective:To explore the clinical efficacy of risperidone sustained release tablets in the treatment of first-episode schizophrenia.Methods:From May 2018 to May 2019,we selected 90 cases of first-episode schizophrenics,who were randomly divided into two groups of 45 cases in each.The control group was treated with risperidone,and the observation group was treated with risperidone sustained release tablets.We compared the efficacy of the two groups.Results:In the observation group,the total score of positive and negative symptom scale(PANSS)at 2 weeks after treatment and the negative score of PANSS at 2 weeks,4 weeks and 8 weeks after treatment were significantly lower than those in the control group,and the difference was statistically significant(P<0.05).There was no significant difference in total effective rate of treatment between groups(P>0.05).In the observation group,the incidence of adverse reactions was significantly lower than that in the control group,and the difference was statistically significant(P<0.05).Conclusion:The effect of palipexone sustained-release tablets in the treatment of first-episode schizophrenia was better,and the incidence of adverse reactions was very low in the whole treatment process,which had high clinical application value.
作者
罗家佳
Luo Jiajia(Psychiatry Department,the Fourth People's Hospital of Rudong County,Jiangsu,Nantong 226400)
出处
《中国社区医师》
2019年第36期39-40,共2页
Chinese Community Doctors
关键词
帕利哌酮缓释片
首发精神分裂症
临床疗效
Risperidone sustained release tablets
First-episode schizophrenia
Clinical efficacy
